{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:35Z","timestamp":1790920535645,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Renal anemia is a common complication of chronic kidney disease (CKD) and is associated with increased cardiovascular morbidity and mortality and reduced quality of life. Long-acting erythropoiesis-stimulating agents (ESAs) offer advantages in dosing convenience and adherence, but a comprehensive multidimensional evaluation comparing these agents within the Chinese healthcare context is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to conduct a multidimensional quantitative evaluation of long-acting ESAs and provide a reference for drug selection and rational clinical use in medical institutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the method recommended in the Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Third Edition), three long-acting ESAs were evaluated in five dimensions, namely, efficacy (28 points), safety (27 points), pharmaceutical properties (27 points), economy (10 points), and other attributes (8 points).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final assessment scores were 80.39 points for the continuous erythropoietin receptor activator (CERA), 73.04 points for pegmolesatide, and 71.70 points for darbepoetin alfa, in descending order. CERA achieved the highest scores in safety and other attributes, darbepoetin alfa ranked first in economy, and pegmolesatide performed best in pharmaceutical properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>According to the scoring results, CERA, pegmolesatide, and darbepoetin alfa all exceeded the guideline-defined threshold for strong recommendation (&amp;gt;70 points) and can be included in the list of strongly recommended drugs for medical institutions. This study provides a scientific, reasonable, and safe basis for medical institutions to select long-acting ESAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1878826","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:36:33Z","timestamp":1790919393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Health technology assessment of long-acting erythropoiesis-stimulating agents for the treatment of renal anemia in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinwen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","place":["Huaian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","place":["Huaian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","place":["Huaian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","place":["Huaian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11255-013-0640-7","article-title":"Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome","volume":"46","author":"Bernieh","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/ckj\/sfac058","article-title":"Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review","volume":"15","author":"Bruce","year":"2022","journal-title":"Clin. Kidney J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cdt3.13","article-title":"Darbepoetin alfa versusepoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: a randomized, open-label, parallel-group, non-inferiority phase III trail","volume":"8","author":"Chen","year":"2022","journal-title":"Chronic Dis. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD010590","DOI":"10.1002\/14651858.CD010590.pub3","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Chung","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3760\/cma.j.cn441217-20250506-00504","article-title":"Clinical practice guidelines for the management of peri-dialysis chronic kidney disease in China (2025 edition)","volume":"41","year":"2025","journal-title":"Chin. J. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD003266","DOI":"10.1002\/14651858.CD003266.pub3","article-title":"Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis","volume":"2016","author":"Cody","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3760\/cma.j.cn441217-20231025-01037","article-title":"Chinese expert consensus on long-acting erythropoiesis-stimulating agents for the treatment of renal anemia (2024 edition)","volume":"40","year":"2024","journal-title":"Chin. J. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/ndt\/gfag014","article-title":"KDIGO 2026 clinical practice guideline for anemia in chronic kidney disease (CKD): a commentary from the european renal best practice (ERBP)","volume":"41","author":"DelVecchio","year":"2026","journal-title":"Nephrol. Dial. Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3760\/cma.j.cn441217-20250121-00143","article-title":"Clinical management guidelines for delaying the progression of chronic kidney disease (2025 edition)","volume":"41","year":"2025","journal-title":"Chin. J. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/089686080902900215","article-title":"Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients","volume":"29","author":"Fang","year":"2009","journal-title":"Perit. Dial. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2215\/CJN.03570417","article-title":"Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD","volume":"13","author":"Fischbach","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40265-012-0002-2","article-title":"Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease","volume":"73","author":"H\u00f6rl","year":"2013","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","article-title":"CKDopps investigators. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis CKD","volume":"30","author":"Hoshino","year":"2020","journal-title":"J. Ren. Nutr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","year":"2026","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1185\/03007990802176467","article-title":"The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A","volume":"24","author":"Kupcov\u00e1","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2147\/DDDT.S499848","article-title":"Health technology assessment: evaluation of 8 CGRP-targeted therapy drugs for the treatment of migraine","volume":"19","author":"Li","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5414\/CN107456","article-title":"Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator","volume":"80","author":"Lim","year":"2013","journal-title":"Clin. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cdt3.23","article-title":"Efficacy and safety of darbepoetin alfa replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: a randomized, open-label, parallel-group, noninferiority phase III trial","volume":"8","author":"Liu","year":"2022","journal-title":"Chronic Dis. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12325-016-0309-6","article-title":"Once-monthly continuous erythropoietin receptor activator (C.E.R.A.) in patients with hemodialysis-dependent chronic kidney disease: pooled data from phase III trials","volume":"33","author":"Locatelli","year":"2016","journal-title":"Adv. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2215\/CJN.01380219","article-title":"Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD: a randomized noninferiority trial","volume":"14","author":"Locatelli","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1648833","DOI":"10.3389\/fphar.2025.1648833","article-title":"Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson's disease","volume":"16","author":"Lv","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMoa074037","article-title":"A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia","volume":"361","author":"Macdougall","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1744-9987.2008.00644.x","article-title":"Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan","volume":"12","author":"Nakagawa","year":"2008","journal-title":"Ther. Apher. Dial."},{"key":"B28","unstructured":"Package insert of pegmolesatide injection [EB\/OL]\n          \n          \n          2023"},{"key":"B29","unstructured":"Bethesda, MD\n          US Department of Health and Human Services, National Institutes of Health, National Cancer Institute\n          Common terminology criteria for adverse events (CTCAE). Version 6\n          \n          2011"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3760\/cma.j.issn.1001-7097.2012.11.006","article-title":"Efficacy, safety and tolerability of continuous erythropoietin receptor activator administered intravenously for correcting anemia in dialysis patients with chronic kidney disease","volume":"28","author":"Qian","year":"2012","journal-title":"Chin. J. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3760\/cma.j.cn112137-20210201-00309","article-title":"Clinical practice guidelines for the diagnosis and treatment of renal anemia in China","volume":"101","year":"2021","journal-title":"Natl. Med. J. China"},{"key":"B33","doi-asserted-by":"publisher","first-page":"CD009904","DOI":"10.1002\/14651858.CD009904.pub2","article-title":"Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease","volume":"8","author":"Saglimbene","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00467-015-3225-0","article-title":"Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study","volume":"31","author":"Schaefer","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12882-019-1209-1","article-title":"Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial","volume":"20","author":"Sinha","year":"2019","journal-title":"BMC Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40620-019-00652-9","article-title":"Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study","volume":"33","author":"Toft","year":"2020","journal-title":"J. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00467-006-0071-0","article-title":"Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease","volume":"21","author":"Warady","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00467-017-3758-5","article-title":"De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease","volume":"33","author":"Warady","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.ajkd.2022.11.006","article-title":"Subcutaneous C.E.R.A. for the maintenance treatment of anemia in pediatric patients with CKD: a phase 2, open-label, single-arm, multicenter study","volume":"81","author":"Warady","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2054358117716461","DOI":"10.1177\/2054358117716461","article-title":"Costs associated with intravenous Darbepoetin versus epoetin therapy in hemodialysis patients: a randomized controlled trial","volume":"30","author":"Woodland","year":"2017","journal-title":"Can. J. Kidney Health Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ekir.2024.12.002","article-title":"Randomized trial of pegmolesatide for the treatment of anemia in patients with nondialysis CKD","volume":"10","author":"Xie","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3870\/j.issn.1004-0781.2024.12.024","article-title":"Cost-effectiveness analysis of roxadustat and darbepoetin alfa for anemia treatment in dialysis-dependent chronic kidney disease patients","volume":"43","author":"Xu","year":"2024","journal-title":"Her. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.eclinm.2023.102273","article-title":"Pegmolesastide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","volume":"65","author":"Zhang","year":"2023","journal-title":"EClinical Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3870\/j.issn.1004-0781.2023.04.001","article-title":"A quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)","volume":"4","author":"Zhao","year":"2023","journal-title":"Her. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3870\/j.issn.1004-0781.2026.01.001","article-title":"A quick guideline for drug evaluation and selection in Chinese medical institutions (the third ddition)","volume":"45","author":"Zhao","year":"2026","journal-title":"Her. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:36:41Z","timestamp":1790919401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":47,"alternative-id":["10.3389\/fphar.2026.1878826"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1878826","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1878826"}}